The estimated Net Worth of Jill Leversage is at least $244 millier dollars as of 21 May 2024. Ms. Leversage owns over 5,610 units of Aurinia Pharmaceuticals Inc stock worth over $84,355 and over the last 4 years she sold AUPH stock worth over $32,201. In addition, she makes $126,980 as Independent Director at Aurinia Pharmaceuticals Inc.
Sign up
Ms. Leversage AUPH stock SEC Form 4 insiders trading
Jill has made over 5 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 5,610 units of AUPH stock worth $32,201 on 21 May 2024.
The largest trade she's ever made was exercising 8,733 units of Aurinia Pharmaceuticals Inc stock on 18 May 2023 worth over $57,026. On average, Jill trades about 2,863 units every 173 days since 2021. As of 21 May 2024 she still owns at least 12,918 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Ms. Leversage stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jill Leversage biography
Jill Diane Leversage serves as Independent Director of the Company. Ms. Jill Leversage was appointed as an independent director in November 2019. Prior to her retirement, Ms. Leversage was a senior investment banker with over 30 years of experience in investment banking and private equity. Ms. Leversage was a Managing Director, Corporate and Investment Banking for TD Securities Inc. and Former Managing Director at Highland West Capital Ltd. She currently serves on several public and private company boards. Ms. Leversage is a fellow of the Institute of Chartered Professional Accountants of British Columbia and also a Chartered Business Valuator (ret.) of the Canadian Institute of Chartered Business Valuators.
What is the salary of Jill Leversage?
As the Independent Director of Aurinia Pharmaceuticals Inc, the total compensation of Jill Leversage at Aurinia Pharmaceuticals Inc is $126,980. There are 17 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
How old is Jill Leversage?
Jill Leversage is 63, she's been the Independent Director of Aurinia Pharmaceuticals Inc since 2019. There are 4 older and 10 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.
What's Jill Leversage's mailing address?
Jill's mailing address filed with the SEC is #140, 14315 - 118 AVENUE, , EDMONTON, A0, T5L 4S6.
Insiders trading at Aurinia Pharmaceuticals Inc
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden et Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
What does Aurinia Pharmaceuticals Inc do?
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
What does Aurinia Pharmaceuticals Inc's logo look like?
Complete history of Ms. Leversage stock trades at Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc executives and stock owners
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Peter Greenleaf,
President, Chief Executive Officer, Director -
Peter S. Greenleaf M.B.A.,
Pres, CEO & Director -
Maxwell Donley,
Executive Vice President, Internal Operations & Strategy -
Neil Solomons,
Chief Marketing Officer -
Massimiliano Colao,
Chief Commercial Officer -
Robert Huizinga,
Executive Vice President - Corporate Development -
Matthew Maxwell Donley M.B.A.,
Exec. VP of Operations & Strategy -
Joseph M. Miller CPA,
Chief Financial Officer -
Dennis Bourgeault,
Chief Financial Officer -
Michael Martin,
Chief Operating Officer -
Daniel Billen,
Director -
George Milne,
Independent Chairman of the Board -
Michael Hayden,
Independent Director -
Stephen P. Robertson,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Joseph Hagan,
Independent Director -
David Jayne,
Independent Director -
R. Hector MacKay-Dunn,
Director -
Jill Leversage,
Independent Director -
Stephen Robertson,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Timothy Walbert,
Independent Director -
Max Colao,
Chief Commercial Officer -
Tim Hermes,
Vice President of Market Access -
Cara Felish,
Vice President of Commercial Operations -
Chris Hays,
Vice President of Marketing -
Fran Lynch,
Vice President of Sales -
Glenn Schulman,
Senior Vice President - Corporate Communications and Investor Relations -
Michael R. Martin,
Chief Bus. Officer -
Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
Exec. VP of Research -
Scott Michael Habig,
Chief Commercial Officer -
Volker Knappertz,
EVP, Research and Development -
Joseph M Miller,
Chief Financial Officer -
Brinda Balakrishnan,
Director -
Robert T Foster,
Director -
Massimilano Colao,
Chief Commercial Officer -
Jeffrey Allen Bailey,
Director -
Karen L. Smith,
Director